IPSC

Century Therapeutics Inc

IPSC, USA

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

https://www.centurytx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IPSC
stock
IPSC

Century Therapeutics Updates on Cell Therapy Advancements TipRanks

Read more →
IPSC
stock
IPSC

Century Therapeutics expands board with new appointments MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$3

Analyst Picks

Strong Buy

3

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.27

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-19.52 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-14.07 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.39

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 28.04% of the total shares of Century Therapeutics Inc

2.

Vanguard Group Inc

(2.4425%)

since

2025/06/30

3.

Renaissance Technologies Corp

(2.3412%)

since

2025/06/30

4.

Dafna Capital Management LLC

(1.9727%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(1.4892%)

since

2025/07/31

6.

Casdin Capital, LLC

(1.4217%)

since

2025/06/30

7.

Syncona Portfolio Ltd.

(1.4042%)

since

2025/06/30

8.

FMR Inc

(1.1814%)

since

2025/06/30

9.

BlackRock Inc

(1.0704%)

since

2025/06/30

10.

TANG CAPITAL MANAGEMENT LLC

(1.0418%)

since

2025/06/30

11.

Millennium Management LLC

(0.9402%)

since

2025/06/30

12.

Two Sigma Investments LLC

(0.6628%)

since

2025/06/30

13.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6247%)

since

2025/07/31

14.

GSA Capital Partners LLP

(0.5401%)

since

2025/06/30

15.

SUPERSTRING CAPITAL MANAGEMENT LP

(0.5359%)

since

2025/06/30

16.

Jane Street Group LLC

(0.5146%)

since

2025/06/30

17.

Geode Capital Management, LLC

(0.4402%)

since

2025/06/30

18.

Two Sigma Advisers, LLC

(0.4249%)

since

2025/06/30

19.

Goldman Sachs Group Inc

(0.3195%)

since

2025/06/30

20.

Susquehanna International Group, LLP

(0.2315%)

since

2025/06/30

21.

Fidelity Extended Market Index

(0.2205%)

since

2025/07/31

22.

Citadel Advisors Llc

(0.2159%)

since

2025/06/30

23.

Fidelity Growth Compy Commingled Pl S

(0.2075%)

since

2025/07/31

24.

Fidelity Growth Company K6

(0.2035%)

since

2025/07/31

25.

Charles Schwab Investment Management Inc

(0.1891%)

since

2025/06/30

26.

Schwab US Small-Cap ETFâ„¢

(0.189%)

since

2025/08/30

27.

Fidelity Global Micro-Cap F

(0.1736%)

since

2025/06/30

28.

Galileo - Biotech Innovation Fund S USD

(0.1445%)

since

2025/02/28

29.

Extended Equity Market Fund K

(0.1129%)

since

2025/06/30

30.

Fidelity Total Market Index

(0.0746%)

since

2025/07/31

31.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0583%)

since

2025/03/31

32.

Fidelity Series Total Market Index

(0.0551%)

since

2025/07/31

33.

Northern Trust Extended Eq Market Idx

(0.054%)

since

2025/06/30

34.

NT Ext Equity Mkt Idx Fd - L

(0.054%)

since

2025/06/30

35.

PGIM Quantitative Solutions US Micro Cap

(0.0526%)

since

2025/06/30

36.

Goldman Sachs Absolute Ret Trckr Instl

(0.0482%)

since

2025/06/30

37.

Spartan Extended Market Index Pool F

(0.0439%)

since

2025/07/31

38.

State Street Russell 2000 Value CIT

(0.0349%)

since

2025/03/31

39.

Spartan Total Market Index Pool G

(0.0278%)

since

2025/07/31

40.

Russell 2000 Index Non-Lendable Fund E

(0.0227%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.3267

Latest Release

Date

2025-09-30

EPS Actual

-0.3199

EPS Estimate

-0.3867

EPS Difference

0.0668

Surprise Percent

17.2744%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(4.5)
Net Net
Strong Net-Net(7)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.